Evidence map›Paper›PMID 42385711›Full record

ArticleCell reports. Medicine2026

Targeted DNA triplex-forming oligonucleotide liposome for pulmonary fibrosis gene therapy.

Jiarui Xu, Ying Xie, Qian Luo, Yuxin Ren, Jinling Wang, Chicheng Qin, Peishan Li, Yixuan Liu, Yuntao Cheng, Min Jiang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiarui XuState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Ying XieState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Qian LuoState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Yuxin RenState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Jinling WangState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Chicheng QinState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Peishan LiState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Yixuan LiuState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Yuntao ChengState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Min JiangState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Yuling ChenState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Dingyi WeiState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Hongrui ZhangState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China.
Jianwei LiState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China. Electronic address: lyy7273@pku.edu.cn.
Wanliang LuState Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, and School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; PKU Medicine-Zhendong Pharmaceutical Joint Laboratory of Advanced Preparation, Health Science Center, Peking University, Beijing 100191, China. Electronic address: luwl@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis is a refractory and serious disease, and there is a need for developing effective clinical treatment strategies. A major cause of pulmonary fibrosis is excessive deposition of extracellular matrix, while the overexpression of plasminogen activator inhibitor 1 (PAI-1) is one of the key drivers of the excessive deposition. Here, we report a targeted DNA triplex-forming oligonucleotide (TFO) liposome (tLipo-TFO1) for pulmonary fibrosis gene therapy to accelerate the clearance of deposited extracellular matrix. tLipo-TFO1 can block the expression of the Serpine1 gene of pulmonary fibrotic cells and thereby downregulate the function of Serpine1-gene-encoded PAI-1 protein. Functional assessments show pulmonary fibrosis-targeting, fibrinolysis-activating effect, as well as significant efficacy in treating pulmonary-fibrosis-bearing mice in vivo. Our study thus suggests that this targeted DNA TFO liposome could be a gene therapy approach for pulmonary fibrosis.

Indexed as

DNAGenetic TherapyLiposomesOligonucleotidesPulmonary FibrosisAnimalsGene Therapy AgentsHumansMaleMiceMice, Inbred C57BLPlasminogen Activator Inhibitor 1DNALiposomesOligonucleotidesPlasminogen Activator Inhibitor 1triplex DNAgene therapyplasminogen activator inhibitorpulmonary fibrosistargeted DNA TFO liposometriplex-forming oligonucleotide

Identifiers

PMID42385711
PMCPMC13522782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.